Histone Deacetylase Inhibitors

Journal of Medicinal Chemistry

Volumn 46, Issue 24, 2003, Pages 5097-5116

  Miller, Thomas A ^a   Witter, David J ^a   Belvedere, Sandro ^a  

^a Aton Pharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; 7 [4 (4 CYANOPHENYL)PHENOXY]HEPTANOHYDROXAMIC ACID; ANILIDE; APICIDIN; BENZAMIDE DERIVATIVE; BENZOFURAN DERIVATIVE; CARBOXYLIC ACID; CL 994; FR 225497; FR 901228; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE; KETONE DERIVATIVE; MEPYRAMINE MALEATE; OXAMFLATIN; PSAMMAPLIN; PYRROLE DERIVATIVE; RADICICOL; SUCCINIMIDE DERIVATIVE; SULFONAMIDE; TAN 1746S; TRAPOXIN B; TUBACIN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER INHIBITION; CELL DIFFERENTIATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; EIMERIA TENELLA; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; NONHUMAN; PHARMACOPHORE; PLASMODIUM FALCIPARUM; REVIEW; SEQUENCE ALIGNMENT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; MODELS, MOLECULAR; SEQUENCE ALIGNMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0242522928     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0303094     Document Type: Review

References (105)

1. Marks, P. A.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 1, 194-202.
2. Kelly, W. K.; O'Connor, O. A.; Marks, P. A. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Invest. Drugs 2002, 11, 1695-1713.
3. Marks, P. A.; Richon, V. M.; Breslow, R.; Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 2001, 13, 477-483.
4. Marks, P. A.; Rifkind, R. A.; Richon, V. M.; Breslow, R. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin. Cancer Res. 2001, 7, 759-760.
5. Meinke, P. T.; Liberator, P. Histone deacetylase: a target for antiproliferative and antiprotozoal agents. Curr. Med. Chem. 2001, 8, 211-235.
6. Grozinger, C. M.; Schreiber, S. L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. 2002, 9, 3-16.
7. Jung, M. Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem. 2001, 8, 1505-1511.
8. Curtin, M. L. Current patent status of histone deacetylase inhibitors. Expert Opin. Ther. Pat. 2002, 12, 1375-1384.
9. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A. ; et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193.
10. Park, H.-J. Y. J.; Kim, Y. K.; Han, J.-W.; Lee, H.-W. Discovery of novel histone deacetylase inhibitors by molecular docking and database screening. MEDI-120 In Abstracts of Papers, 224th National Meeting of the American Chemical Society, Boston, MA; American Chemical Society: Washington, DC, 2002 (CODEN: 69CZPZ Conference, meeting abstract written in English).
11. Mai, A.; Massa, S.; Ragno, R.; Esposito, M.; Sbardella, G.; et al. Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation. J. Med. Chem. 2002, 45, 1778-1784.
12. Mai, A.; Massa, S.; Ragno, R.; Cerbara, I.; Jesacher, F.; et al. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures. J. Med. Chem. 2003, 46, 512-524.
13. Remiszewski, S. W.; Sambucetti, L. C.; Atadja, P.; Bair, K. W.; Cornell, W. D.; et al. Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J. Med. Chem. 2002, 45, 753-757.
14. Van Ommeslaeghe, K. E. G.; Brecx, V.; Papeleu, P.; Iterbeke, K.; Geerlings, P.; Tourwe, D.; Rogiers, V. Amide analogues of TSA: synthesis, binding mode analysis and HDAC inhibition. Bioorg. Med. Chem. Lett. 2003, 13, 1861-1864.
15. Tsuji, N.; Kobayashi, M.; Nagashima, K.; Wakisaka, Y.; Koizumi, K. A new antifungal antibiotic, trichostatin. J. Antibiot. 1976, 29, 1-6.
16. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265, 17174-17179.
17. Yoshida, M.; Hoshikawa, Y.; Koseki, K.; Mori, K.; Beppu, T. Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. J. Antibiot. 1990, 43, 1101-1106.
18. Mori, K.; Koseki, K. Synthesis of trichostatin A, a potent differentiation inducer of Friend leukemic cells, and its antipode. Tetrahedron 1998, 44, 6013-6020.
19. Richon, V. M.; Webb, Y.; Merger, R.; Sheppard, T.; Jursic, B.; et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 5705-5708.
20. Richon, V. M.; Emiliani, S.; Verdin, E.; Webb, Y.; Breslow, R.; et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 3003-3007.
21. Breslow, R.; Belvedere, S.; Gershell, L. Development of cyto-differentiating agents for cancer chemotherapy. Helv. Chim. Acta 2000, 83, 1685-1692.
22. Richon, V. M.; Zhou, X.; Rifkind, R. A.; Marks, P. A. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells, Mol. Dis. 2001, 27, 260-264.
23. Marks, P. A.; Richon, V. M.; Rifkind, R. A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 2000, 92, 1210-1216.
24. Kim, Y. B.; Lee, K. H.; Sugita, K.; Yoshida, M.; Horinouchi, S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 1999, 18, 2461-2470.
25. Ohtani, M.; Matsuura, T.; Shirahase, K.; Sugita, K. (2E)-5-[3-[(Phenylsulfonyl)amino]phenyl]-pent-2-pent-2-en-4-ynohydroxamic acid and its derivatives as novel and potent inhibitors of ras transformation. J. Med. Chem. 1996, 39, 2871-2873.
26. Su, G. H.; Sohn, T. A.; Ryu, B.; Kern, S. E. A Novel Histone Deacetylase Inhibitor Identified by High-Throughput Transcriptional Screening of a Compound Library. Cancer Res. 2000, 60, 3137-3142.
27. Tricyclic lactam and sultam derivatives as histone deacetylase inhibitors: Wo02062773. Expert Opin. Ther. Pat. 2003, 13, 387-391.
28. Jung, M.; Hoffmann, K.; Brosch, G.; Loid, P. Analogues of trichostatin A and trapoxin B as histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 1997, 7, 1655-1658.
29. Wittich, S.; Scherf, H.; Xie, C.; Brosch, G.; Loidl, P.; et al. Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. J. Med. Chem. 2002, 45, 3296-3309.
30. Jung, M.; Brosch, G.; Kölle, D.; Scherf, H.; Gerhäuser, C.; et al. Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation. J. Med. Chem. 1999, 42, 4669-4679.
31. Breslow, R.; Marks, P. A.; Rifkind, R. Potent inducers of terminal differentiation and methods of use thereof. U.S. Patent 5,700,-811, 1997.
32. Woo, S. H.; Frechette, S.; Abou Khalil, E.; Bouchain, G.; Vaisburg, A.; et al. Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. J. Med. Chem. 2002, 45, 2877-2885.
33. Glaser, K. B.; Li, J.; Aakre, M. E.; Morgan, D. W.; Sheppard, G.; et al. Transforming growth factor beta mimetics: discovery of 7-[4-(4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a bi-aryl hydroxamate inhibitor of histone deacetylase. Mol. Cancer Ther. 2002, 1, 759-768.
34. Curtin, M. L.; Garland, R. B.; Heyman, H. R.; Frey, R. R.; Michaelides, M. R.; et al. Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC). Bioorg. Med. Chem. Lett. 2002, 12, 2919-2923.
35. Dai, Y.; Guo, Y.; Guo, J.; Pease, L. J.; Li, J.; et al. Indole amide hydroxamic acids as potent inhibitors of histone deacetylases. Bioorg. Med. Chem. Lett. 2003, 13, 1897-1901.
36. Sternson, S. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org. Lett. 2001, 3, 4239-4242.
37. Breslow, R.; Belvedere, S.; Gershell, L.; Miller, T. A.; Marks, P. A.; et al. Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof. U.S. Patent 6,511,990-B1, 2003.
38. Lavoie, R.; Bouchain, G.; Frechette, S.; Woo, S. H.; Khalil, E. A.; et al. Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 2847-2850.
39. Bouchain, G.; Leit, S.; Frechette, S.; Khalil, E. A.; Lavoie, R.; et al. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors. J. Med. Chem. 2003, 46, 820-830.
40. Uesato, S.; Kitagawa, M.; Nagaoka, Y.; Maeda, T.; Kuwajima, H.; et al. Novel histone deacetylase inhibitors: N-hydroxycar-boxamides possessing a terminal bicyclic aryl group. Bioorg. Med. Chem. Lett. 2002, 12, 1347-1349.
41. Massa, S.; Artico, M.; Corelli, F.; Mai, A.; Di Santo, R.; et al. Synthesis and antimicrobial and cytotoxic activities of pyrrole-containing analogs of trichostatin A. J. Med. Chem. 1990, 33, 2845-2849.
42. Massa, S.; Mai, A.; Sbardella, G.; Esposito, M.; Ragno, R.; et al. 3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. J. Med. Chem. 2001, 44, 2069-2072.
43. Perez, L. B.; Remiszewski, S. W.; Sambucetti, L. C.; Atadja, P.; Blair, K. W.; et al. Discovery and SAR of NVP-LAQ824: novel histone deacetylase inhibitor with in vitro and in vivo antitumor activity. Presented at the Meeting of the American Association for Cancer Research, San Francisco, CA, 2002; Abstract 3671.
44. Remiszewski, S. W.; Bobadilla, M.; Bontempo, J.; Brouillard, J. F.; Cesarz, D.; et al. Preclinical efficacy, toxicology and pharmacokinetics of NPV-LAQ824, a novel histone deacetylase inhibitor. Presented at the 14th EORTC-NCI-AACR, Frankfurt, Germany, 2002; Abstract 326.
45. Chen, J. S.; Faller, D. V. Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer, Curr. Cancer Drug Targets 2003, 3, 219-236.
46. Cummings, J. I. Short chain fatty acids in the human colon. Gut 1981, 22, 763-779.
47. Watson, J.; Glasg, M. B. Butyric acid in the treatment of cancer, Lancet 1933, 746-748.
48. Gottlicher, M.; Minucci, S.; Zhu, P.; Kramer, O. H.; Schimpf, A.; et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20, 6969-6978.
49. Jeong, M. R.; Hashimoto, R.; Senatorov, V. V.; Fujimaki, K.; Ren, M.; et al. Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Lett. 2003, 542, 74-78.
50. Phiel, C. J.; Zhang, F.; Huang, E. Y.; Guenther, M. G.; Lazar, M. A.; et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 2001, 276, 36734-36741.
51. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discovery 2002, 1, 287-299.
52. Warrell, R. P., Jr.; He, L. Z.; Richon, V.; Calleja, E.; Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 1998, 90, 1621-1625.
53. Rephaeli, A.; Zhuk, R.; Nudelman, A. Prodrugs of butyric acid from bench to bedside: synthetic design, mechanism of action, and clinical applications. Drug Dev. Res. 2000, 50, 379-391.
54. Suzuki, T.; Ando, T.; Tsuchiya, K.; Fukazawa, N.; Saito, A.; et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. 1999, 42, 3001-3003.
55. El-Beltagi, H. M.; Martens, A. C. M.; Lelieveld, P.; Haroun, E. A.; Hagenbeek, A. Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells-preclinical studies in a relevant rat model for human acute myelocytic leukemia. Cancer Res. 1993, 53, 3008-3014.
56. Seelig, M. H.; Berger, M. R. Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro. Eur. J. Cancer 1996, 32A, 1968-1976.
57. Saito, A.; Yamashita, T.; Mariko, Y.; Nosaka, Y.; Tsuchiya, K.; et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4592-4597.
58. Jaboin, J.; Wild, J.; Hamidi, H.; Khanna, C.; Kim, C. J.; et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 2002, 62, 6108-6115.
59. Prakash, S.; Foster, B. J.; Meyer, M.; Wozniak, A.; Heilbrun, L. K.; et al. Chronic oral administration of CI-994: a phase I study. Invest. New Drugs 2001, 19, 1-11.
60. Ardizzoni, A.; Loprevite, M. Histone deacylation inhibitors. Tumori 2002, 88 (Suppl.), S52-S54.
61. Fournel, M.; Trachy-Bourget, M.-C.; Yan, P. T.; Kalita, A.; Bonfils, C.; et al. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res. 2002, 62, 4325-4330.
62. Wong, J. C.; Hong, R.; Schreiber, S. L. Structural biasing elements for in-cell histone deacetylase paralog selectivity. J. Am. Chem. Soc. 2003, 125, 5586-5587.
63. Glaser, K. B.; Staver, M. J.; Waring, J. F.; Stender, J.; Ulrich, R. G.; et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2003, 2, 151-163.
64. Christianson, D. W.; Lipscomb, W. N. The complex between carboxypeptidase A and a possible transition-state analogue: mechanistic inferences from high-resolution X-ray structures of enzyme-inhibitor complexes. J. Am. Chem. Soc. 1986, 108, 4998-5003.
65. Walter, M. W.; Felici, A.; Galleni, M.; Soto, R. P.; Adlington, R. M.; et al. Trifluoromethyl alcohol and ketone inhibitors of metallo-beta-lactamases. Bioorg. Med. Chem. Lett. 1996, 6, 2455-2458.
66. Frey, R. R.; Wada, C. K.; Garland, R. B.; Curtin, M. L.; Michaelides, M. R.; et al. Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett. 2002, 12, 3443-3447.
67. Frey, R. R.; Curtin, M. L.; Garland, R. B.; Wada, C. K.; Vasudevan, A.; et al. Electrophilic ketone-based histone deacetylase (HDAC) inhibitors as cancer chemotherapeutic agents. Presented at the 224th National Meeting of the American Chemical Society, Boston, MA, 2002.
68. Marshall, J. L.; Rizvi, N.; Kauh, J.; Dahut, W.; Figuera, M.; et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol. 2002, 2, 325-332.
69. Sandor, V.; Bakke, S.; Robey, R. W.; Kang, M. H.; Blagosklonny, M. V.; et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 2002, 8, 718-728.
70. Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 1993, 268, 22429-22435.
71. Komatsu, Y.; Tomizaki, K.-Y.; Tsukamoto, M.; Kato, T.; Nishino, N.; et al. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res. 2001, 61, 4459-4466.
72. Gross, M. L.; McCrery, D.; Crow, F.; Tomer, K. B. The structure of the toxin from Helminthosporium carbonum. Tetrahedron Lett. 1982, 23, 5381-5384.
73. Liesch, J. M.; Sweeley, C. C.; Staffeld, G. D.; Anderson, M. S.; Weber, D. J.; Scheffer, R. P. Structure of HC-toxin, a cyclic tetrapeptide from Helminthosporium carbonum. Tetrahedron Lett. 1982, 38, 45-48.
74. Kim, S.-D.; Knoche, H. W. Structure of an amino acid analog of the host-specific toxin from Helminthosporium carbonum. Tetrahedron Lett. 1985, 26, 969-972.
75. Tanis, S. P.; Horenstein, B. A.; Scheffer, R. P.; Rasmussen, J. B. A new host specific toxin from Helminthosporium carbonum. Heterocycles 1986, 24, 3423-3431.
76. Hirota, A.; Suzuki, A.; Suzuki, H.; Tamura, S. Isolation and biological activity of Cyl-2, a metabolite of Cylindrocladium scoparium. Agric. Biol. Chem. 1973, 37, 643-647.
77. Hirota, A.; Suzuki, A.; Suzuki, H.; Aizawa, K.; Tamura, S. Structure of Cyl-2, a novel cyclotetrapeptide from Cylindrocladium scoparium. Agric. Biol. Chem. 1973, 37, 955-956.
78. Hirota, A.; Suzuki, A.; Suzuki, H.; Tamura, S. Characterization of four amino acids constituting Cyl-2, a metabolite from Cylindrocladium scoparium. Agric. Biol. Chem. 1973, 37, 1185-1189.
79. Kawai, M.; Pottorf, R. S.; Rich, D. H. Structure and solution conformation of the cytostatic cyclic tetrapeptide WF-3161, cyclo-[L-leucyl-L-pipecolyl-L-(2-amino-8-oxo-9,10-epoxydecanoyl)-D-phenylalanyl] . J. Med. Chem. 1986, 29, 2409-2411.
80. Umehara, K.; Nakahara, K.; Kiyoto, S.; Iwami, M.; Okamoto, M.; Tanaka, H.; Kohsaka, M.; Aoki, H.; Imanaka, H. Studies on WF-3161, a new antitumor antibiotic. J. Antibiot. 1983, 36, 478-483.
81. Itazaki, H.; Nagashima, K.; Sugita, K.; Yoshida, H.; Kawamura, Y.; Yasuda, Y.; Matsumoto, K.; Ishii, K.; Uotani, N.; Nakai, H.; Terui, A.; Yoshimatsu, S.; Ikenishi, Y.; Nakawaga, Y. Isolation and structural elucidation of new cyclotetrapeptides, trapoxin A and B, having detransformation activities as antitumor agents. J. Antibiot. 1990, 63, 1524-1532.
82. Closse, A.; Huguenin, R. Isolation and structural clarification of chlamydocin. Helv. Chim. Acta 1974, 57, 533-545.
83. Ciuffetti, L. M.; Pope, M. R.; Dunkle, L. D.; Daly, J. M.; Knoche, H. W. Isolation and structure of an inactive product derived from the host-specific toxin produced by Helminthosporium carbonum. Biochemistry 1983, 22, 3507-3510.
84. Taunton, J.; Hassig, C. A.; Schreiber, S. L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996, 272, 408-411.
85. Taunton, J.; Collins, J. L.; Schreiber, S. L. Synthesis of natural and modified trapoxins, useful reagents for exploring histone deacetylase function. J. Am. Chem. Soc. 1996, 118, 10412-10422.
86. Hassig, C. A.; Tong, J. K.; Fleischer, T. C.; Owa, T.; Grable, P. G.; et al. A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 3519-3524.
87. Singh, S. B.; Zink, D. L.; Polishook, J. D.; Dombrowski, A. W.; Darkin-Rattray, S. J.; Schmatz, D. M.; Goetz, M. A. Apicidins: novel cyclic tetrapeptides as coccidiostats and antimalarial agents from Fusarium pallidoroseum. Tetrahedron Lett. 1996, 37, 8077-8080.
88. Darkin-Rattray, S. J.; Gurnett, A. M.; Myers, R. W.; Dulski, P. M.; Crumley, T. M.; et al. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 13143-13147.
89. Singh, S. B.; Zink, D. L.; Liesch, J. M.; Dombrowski, A. W.; Darkin-Rattray, S. J.; et al. Structure, histone deacetylase, and antiprotozoal activities of apicidins B and C, congeners of apicidin with proline and valine substitutions. Org. Lett. 2001, 3, 2815-2818.
90. Singh, S. B.; Zink, D. L.; Liesch, J. M.; Mosley, R. T.; Dombrowski, A. W.; et al. Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal α-keto epoxide as inhibitors of histone deacetylase with potent anti-protozoal activities. J. Org. Chem. 2002, 67, 815-825.
91. Abe, F.; Hino, M.; Mori, H.; Yoshimura, S.; Takase, S. Inhibitor of histone deacetylase. WO200008048-A2, 2000.
92. Gupta, S.; Peiser, G.; Nakajima, T.; Hwang, Y.-S. Characterization of a phytotoxic cyclotetrapeptide, a novel chlamydocin analogue, from Verticillium coccosporum. Tetrahedron Lett. 1994, 35, 6009-6012,
93. Motohiro, H.; Hiroaki, M.; Kazutoshi, S.; Shigehiro, T.; Yasuhisa, T.; et al. Cyclic Tetrapeptide and Use Thereof. WO200021979, 2000.
94. Yoshimura, K.; Tsubotani, S.; Okazaki, K. Tan1746 compounds, their production and use thereof. JP 7196686, 1995,
95. Colletti, S. L.; Myers, R. W.; Darkin-Rattray, S. J.; Gurnett, A. M.; Dulski, P. M.; et al. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 1. Bioorg. Med. Chem. Lett. 2001, 11, 107-111.
96. Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Yoshida, M.; et al. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 87-92.
97. Nishino, H.; Tomizaki, K.-Y.; Kato, T.; Nishino, N.; Yoshida, M.; et al. Synthesis of cyclic tetrapeptides containing non-natural imino acids. Peptide Sci. 1999, 189-192.
98. Colletti, S. L.; Myers, R. W.; Darkin-Rattray, S. J.; Gurnett, A. M.; Dulski, P. M.; et al. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 2. Bioorg. Med. Chem. Lett. 2001, 11, 113-117.
99. Ueda, H.; Nakajima, H.; Heri, Y.; Fujita, T.; Nishimura, M.; Goto, T.; Okuhara, M. FR901228, A novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. J. Antibiot. 1994, 47, 301-310.
100. Shigematsu, N.; Ueda, H.; Takase, S.; Tanaka, H. FR9011228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. J. Antibiot. 1994, 47, 311-314.
101. Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K. H.; Nishiyama, M.; et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002, 62, 4916-4921.
102. Kwon, H. J.; Owa, T.; Hassig, C. A.; Shimada, J.; Schreiber, S. L. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 3356-3361.
103. Pina, I. C.; Gautschi, J. T.; Wang, G. Y.; Sanders, M. L.; Schmitz, F. J.; et al. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem. 2003, 68, 3866-3873.
104. Matsuyama, A.; Shimazu, T.; Sumida, Y.; Saito, A.; Yoshimatsu, Y.; et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 2002, 21, 6820-6831.
105. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4389-4394.